Affiliation:
1. Radiology
2. Neurological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Abstract
Abstract
18F-THK5351 demonstrates a strong binding affinity and selectivity for tau. However, off-target binding with monoamine oxidase-B enzyme, highly expressed in the outer mitochondrial membranes of astrocytes, is possible. In a case with isocitrate dehydrogenase–wildtype glioblastoma, 11C-MET PET and 18F-THK5351 PET exhibited increased uptake in the tumor. Conversely, in another case with intracranial meningioma, MET PET revealed increased uptake in the tumor, whereas 18F-THK5351 PET showed no abnormal uptake in the tumor. However, it is challenging to distinguish meningiomas from glioblastomas on MRI. 18F-THK5351 PET might help differentiate between isocitrate dehydrogenase–wildtype glioblastoma and meningioma.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference10 articles.
1. Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015-2019;Neurooncol Pract,2023
2. Correlation of 18F-FDG and 11C-methionine uptake on PET/CT with Ki-67 immunohistochemistry in newly diagnosed intracranial meningiomas;Ann Nucl Med,2018
3. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease;J Nucl Med,2016
4. Structure-activity relationship of 2-arylquinolines as PET imaging tracers for tau pathology in Alzheimer disease;J Nucl Med,2016
5. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain;Alzheimers Res Ther,2017